We tested the utility of intratracheal carbon dioxide monitoring (IT-CO 2 ) in 10 patients undergoing percutaneous dilatational tracheostomy (PDT). We have found IT-CO 2 monitoring reliable in confirming the correct position of the tracheal cannula prior to tracheal dilatation using the Portex technique.
Percutaneous dilatational tracheostomy (PDT) has become an established technique in the Intensive Care Unit (ICU) since its widespread introduction in 1985 1 . It is preferred to surgical tracheostomy in the majority of critically ill patients 2 . We have used the Portex PDT technique (Portex Ltd, U.K.) routinely in the ICU since its introduction to Australia in January 1995. The technique requires the placement of a cannula into the trachea, as the initial step, prior to insertion of a guidewire. This is followed by tracheal dilatation using modified Howard-Kelly forceps placed over the wire, and insertion of a standard 8.0 mm or 9.0 mm tracheostomy tube 3 .
Verification of correct cannula and subsequent guidewire placement is vital to avoid injury to surrounding structures during the tracheal dilatation. Complications are uncommon 4 , but can result in significant morbidity when they occur 5 . Many practitioners use fibreoptic bronchoscopy to confirm tracheal placement and ensure that the trachea has been punctured close to the midline 6,7 . However, bronchoscopy can cause an increase in proximal air-way pressures and a reduction in delivered tidal volume 8 , causing difficulties with ventilation in some patients. In addition, access to and experience with bronchoscopy is not available in all centres. We reserve bronchoscopy for patients in whom additional difficulties with the procedure or with maintenance of the airway are anticipated. For routine PDT, we have used intratracheal carbon dioxide (IT-CO 2 ) monitoring to confirm tracheal placement of the cannula prior to dilatation of the trachea. This is in addition to the aspiration of air from the tracheal air column and unimpeded passage of the guidewire as a marker of correct placement in the trachea.
METHOD
Ten patients underwent PDT using the Portex technique. Anaesthesia was induced and maintained with propofol and neuromuscular blockade achieved with vecuronium. A standard operator approach was used and the trachea punctured in the midline under strict aseptic conditions with the cannula-over-needle provided in the Portex kit. Air was aspirated into the attached saline-filled syringe, and the cannula advanced. The sterile male luer connector of the sample line from a POET II end-tidal CO 2 analyser (Criticare Systems Inc, U.S.A.) was attached to the cannula and the CO 2 waveform analysed.
RESULTS
A CO 2 waveform was obtained immediately using this technique in all ten patients and intratracheal placement of the cannula was confirmed with fibreoptic bronchoscopy in each case. The PDT procedure was completed and there were no complications.
DISCUSSION
While many operators use fibreoptic bronchoscopy routinely during PDT, we believe that in experienced hands the Portex technique can be performed safely without it. Intratracheal CO 2 monitoring has been recommended to confirm correct placement of the tracheostomy tube before mechanical ventilation is commenced, as paratracheal placement of the tube is a recognised complication 5 . We have demonstrated that intra-tracheal CO 2 sidestream monitoring is also an easy and effective method of confirming correct placement of the guidewire in the trachea prior to tracheal dilatation, thus minimizing the risk of damage to the trachea and surrounding structures during dilatation. Although we have not investigated the method, it is possible that in-line CO 2 monitoring could be used instead of sidestream monitoring for this purpose.
